The Counter-Regulation of Atherogenesis: a Role for Interleukin-33
Pavel Kuneš,
Zdeňka Holubcová,
Martina Koláčková,
Jan Krejsek
Affiliations
Pavel Kuneš
Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Cardiac Surgery, Hradec Králové, Czech Republic; Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
Zdeňka Holubcová
Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Cardiac Surgery, Hradec Králové, Czech Republic
Martina Koláčková
Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
Jan Krejsek
Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
The recently recognized cytokine interleukin-33 and its receptor ST2 play a favorable role during atherogenesis by inducing a Th1→Th2 shift of the immune response. IL-33 also protects the failing human heart from harmful biomechanical forces which lead to cardiomyocyte hypertrophy and exaggerated interstitial fibrosis. IL-33 inevitably displays side effects common to other Th2 cytokines, the most grave of which is a predisposition to allergic reactions. IL-33 is a nuclear transcription factor of endothelial cells. As such, it is abundant in nonproliferating vessels. Its down-regulation is required for angiogenesis, which may be profitable in wound healing or deleterious in tumor growth.